LONG PEPTIDES OF 22-45 AMINO ACID RESIDUES THAT INDUCE AND/OR ENHANCE ANTIGEN SPECIFIC IMMUNE RESPONSES

Abstract

Epitopes derived from human papilloma virus and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes are disclosed. Also disclosed are clinically relevant approaches for immunizing subjects against (Myco) bacterially and/or virally infected cells or tumor cells. Peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides. Also disclosed are clinically relevant approaches for vaccination and/or treatment of subjects against HPV and methods and uses suited to treat subjects suffering from progressive lesions and/or cervical cancer.

Claims

1. An immunogenic composition comprising a peptide having a length of 22 to 45 amino acids that comprises a T helper cell epitope consisting of residues 35-50 of the E7 protein of a type 16 human papilloma virus (HPV), and an adjuvant.

2. The immunogenic composition of claim 1, wherein the peptide has a length of 22-40 amino acids.

3. The immunogenic composition of claim 1, wherein the peptide has a length of 22-35 amino acids.

4. The immunogenic composition of claim 1, wherein the peptide has a length of 32-35 amino acids.

5. The immunogenic composition of claim 1, wherein the peptide consists of the HPV16 E7 protein segment consisting of residues 35-55, 30-50, 31-52 or 22-56 of HPV 16 E7.

6. The immunogenic composition of claim 1, wherein the peptide consists of the HPV16 E7 protein segment consisting of residues 22-56 of HPV 16 E7.

7. The immunogenic composition according claim 1, further comprising a peptide comprising a fragment of HPV 16 E2 protein comprising residues 46-75, 51-70, 61-76, 311-325, 316-330, 346-355 or 351-365 of HPV16 E2.

8. The immunogenic composition according claim 1, further comprising a peptide comprising a fragment of HPV 16 E7 protein comprising residues 50-62 or 43-77 of HPV 16 E7.

9. The immunogenic composition according to claim 1, further comprising a peptide comprising a fragment of HPV 16 E6protein comprising residues 121-142 or 127-140 of HPV 16 E6.

10. The immunogenic composition according to claim 1, wherein the adjuvant is selected from the group consisting of (a) an exosome, (b) poly I:C, (c) poly I:poly C12U, (d) monophosphoryl lipid A, (e) a CpG-containing nucleic acid, (f) a CD40 ligand, and (g) a mixture of any of (a)-(f).

11. The immunogenic composition of claim 10, wherein the CD40 ligand is an anti-CD40 antibody.

Description

BRIEF DESCRIPTION OF THE FIGURES

[0150] FIGS. 1a-1d depict the peptide E741-62 induced T-cell response that recognizes naturally processed antigen (Ag). PBMC from a healthy HLA-DR15, 4 and DQ6,7 positive blood donor were stimulated four times with peptide E7.sub.41-62. The responding T-cells were tested in a 3-day proliferation assay (FIGS. 1a, 1b, and 1c) or stimulated for 1 day in order to measure the production of IFN by ELISA (d). Responder cells (R) and autologous or MHC class II matched antigen presenting cells (A) were incubated with the indicated Ags: recombinant HPV16 E6 protein (E6), recombinant HPV16 E7 protein (E7), recombinant HIV RT protein (RT) or peptides derived from E6(eg E6.sub.81-102, peptide E6.sub.81-102) or derived from E7. Proliferation of the bulk T-cell culture (FIG. 1a), proliferation of the T-helper clone, derived from the bulk T-cell culture, and blocking of the E7 proteinspecific response by adding an antibody against HLA-DR (FIG. 1b), proliferation of the T-helper clone when stimulated with partially MHC class II matched antigen presenting cells (FIG. 1c), and fine mapping of the minimal epitope by measurement of the IFN production per 24 h by the T-helper clone (FIG. 1d).

[0151] FIGS. 2a-2c depict a peptide E7.sub.22-56 induced T-cell response that recognizes naturally processed Ag. PBMC from a healthy HLA-DR3 and DQ2 positive blood donor were stimulated four times with peptide E7.sub.22-56 Proliferation of the bulk T-cell culture (FIG. 2a), specific proliferation of the T-helper clone, derived from the bulk T-cell culture, when stimulated with E7.sub.22-56, E.sup.7.sub.31-52 and E7 protein (FIG. 2b), and fine mapping of the minimal epitope and MHC class II restriction by measurement of the IFN production per 24 h of the T-helper cell clone (FIG. 2c). (See, also, FIGS. 1a-1d and associated descriptions).

[0152] FIGS. 3a-3e depict a peptide E7.sub.43-77 induced T-cell response that recognizes naturally processed Ag. PBMC from a healthy HLA-DR1,3 and DQ2 positive blood donor were stimulated four times with peptide E7.sub.43-77. Proliferation of the bulk T-cell culture (FIG. 3a), specific proliferation of the T-helper cell clone against peptide E7.sub.43-77 and E7 protein (FIG. 3b), recognition of partially matched (DR3, DQ2) peptide pulsed antigen presenting cell (APC) (FIG. 3c) anti HLA-DR antibody blocks the E7-specific proliferation of the T-helper cell clone revealing HLA-DR3 as restriction element (FIG. 3d), and specific production of IFN by the T-helper cell clone when stimulated with E.sup.7.sub.43-77 peptide or E7 protein (FIG. 3e). (See, also, FIGS. 1a-1d and associated descriptions).

[0153] FIG. 4 depicts the stimulation with influenza matrix 1 (M1)-peptides of MACSseparated CD45RA+ (naive) T-cells (left) and CD45RO+ (memory) T-cells (right) results in the production of IFN in the CD45RO+ subset only. The MI protein was divided in 16 overlapping peptides. Each pool consists of four 30 amino acid long peptides that overlap by 15 amino acids. Tet. tox.: tetanus toxoid.

[0154] FIGS. 5a-5d depict a peptides E2.sub.301-330 and E2.sub.316-345 induced T-cell response that recognizes naturally processed Ag. PBMC from a healthy HLA-DR2 positive blood donor were stimulated four times with peptides E2.sub.301-330 and E2.sub.316-345. Specific proliferation of the T-helper cell clone against peptide E2.sub.301-330 and E2.sub.316-345 and E2 protein (FIG. 5a), specific production of IFN by the T-helper cell clone when stimulated with E2.sub.301-330 and E2.sub.316-345 peptides (FIG. 5b), fine-mapping of the minimal epitope E2.sub.316-330 (FIG. 5c) and anti HLA-DR antibody blocks the E2-specific IFN production of the T-helper cell clone revealing HLA-DR2 as restriction element (FIG. 5d),. (See, also, FIGS. 1a-1d and associated descriptions).

[0155] FIGS. 6a-6d depict a peptides E2.sub.301-330 and E2.sub.316-345. induced T-cell response that recognizes naturally processed Ag. PBMC from a healthy HLA-DR2, DQ6 (1) positive blood donor were stimulated four times with peptides E2.sub.301-330 and E2.sub.316-345. Specific proliferation of the T-helper cell clone against peptide E2.sub.301-330 and E2 protein (FIG. 6a), specific production of IFN by the T-helper cell clone when stimulated with E2.sub.301-330 (FIG. 6b), fine-mapping of the minimal epitope E23.sub.311-325 (FIG. 6c), and anti HLA-DQ antibody blocks the E2-specific IFN production of the T-helper cell clone revealing HLA-DQ6 (1) as restriction element (d). (See, also, FIGS. 1a-1d and associated descriptions).

[0156] FIGS. 7a-7d depict a peptide E2.sub.331-365 induced T-cell response that recognizes naturally processed Ag. PBMC from a healthy HLA-DR2 positive blood donor were stimulated four times with peptide E2.sub.331-365. Specific proliferation of the T-helper cell clone against peptide E2.sub.331-365 and E2 protein (FIG. 7a), specific production of IFN by the T-helper cell clone when stimulated with E2331-365 peptide (FIG. 7b), fine-mapping of the minimal epitope E2.sub.346-355 (FIG. 7c) and anti HLA-DR antibody blocks the E2-specific IFN production of the T helper cell clone revealing HLA-DR2 as restriction element (FIG. 7d). (See, also, FIGS. 1a-1d and associated descriptions).

[0157] FIGS. 8a-8c depict a peptide E2.sub.331-365 induced T-cell response that recognizes naturally processed Ag. PBMC from a healthy HLA-DR1 positive blood donor were stimulated four times with peptide E2331.36s. Specific proliferation of the T-helper cell clone against peptide E2.sub.331-365 and E2 protein (FIG. 8a), fine-mapping of the minimal epitope E2.sub.351-365 (FIG. 8b), and anti HLA-DR antibody blocks the E2-specific IFN production of the T-helper cell clone revealing HLA-DR1 as restriction element (FIG. 8c). (See, also, FIGS. 1a-1d and associated descriptions).

[0158] FIGS. 9a-9f depict E2-peptide specific IFN -production of T-cells present in the CD45RO+ (memory)-fraction of PBMC. The CD45RO+ memory fraction of PBMC were isolated using MACS technology. Following separation these memory T-cells were stimulated with indicated peptides. After 10 days of incubation the cells were harvested, washed and then stimulated with the indicated peptides in a 96-well ELISPOT plate at 50,000 PBMC per well. The number of IFN -producing T-cells per 50,000 PBMC is indicated on the Y-axis of each of FIGS. 9a-9f, Healthy blood donor derived CD45RO+ PBMC contain HPV16 E2specific memory T-cells as shown by the reaction to several pools of : two 30 amino acid long E2 peptides (first amino acid of first peptide and last amino acid of second peptide are indicated at X-axis) that were selected based on immunogenicity of these peptides, which was established in previous assays (FIGS. 9a-9b), or four 30 amino acid long E2 peptides (indicated are the position of the first and last amino acid of the sequence that is covered by these 4 peptides in the E2-protein) (FIGS. 9d-9f). MRM: memory response mix which consists of a mix of Mycobacterium tuberculosis, Tetanus toxoid and Candida albicans antigens. (See, also, FIG. 4, and associated description). *, statistically significant response (p<0. 05).

[0159] FIG. 10 depicts the survival of C57/B16 mice when immunized once with 30 g of the 32 amino acid long peptide (RECNSSTDSCDSGPSNTPPEIHPVVRLCPIIKP) (SEQ. ID. NO. 2) containing the minimal CTL epitope. Mice were challenged 14 days later with 0.5 million ARS tumor cells at the opposite flank. In contrast, mice immunized with the minimal 10 amino acid long CTL epitope (SGPSNTPPEI) (SEQ. ID. NO. 1) were not protected.

[0160] FIGS. 11a-11e depict how MHC class II T helper cells enhance E7.sup.49-57-specific CTL responses following prime-boost vaccinations with the HPV16 E7.sup.43-77 35-mer. Mice (B6) were either primed once with E7.sup.49-57 peptide (FIG. 11a) or E7.sup.43-77 35-mer (FIG. 11b), or boosted 50 days later with the same peptides: E7.sup.49-57 peptide (FIG. 11c) or E7.sup.43-77 35-mer (FIG. 11d). MHC class II.sup./ mice were similarly primed and boosted with .sup.E743-77 35-mer (FIG. 11e). Peptides were emulsified in IFA. Ten days following the final vaccination spleens were harvested and cultures were stimulated with the E7.sup.49-57-expressing tumor cell line 13.2. Based on the forward and side scatter pattern of isolated spleen cells in the FACS, CD8 (FL4-H) staining and H-2D.sup.b-RAHYNIVTF (SEQ. ID. NO. 3)tetramers staining spleen cells are subjected to the analysis of CD8+ H-2D.sup.b-RAHYNIVTF SEQ. ID. NO. 3)tetramer positive T-cells. Indicated on the y-axis are the percentage of CD8+ T-cells that were H-2D.sup.b-RAHYNIVTF (SEQ. ID. NO. 3)tetramers positive. Each column on the x-axis represents an individual mouse. The horizontal line indicates background responses plus standard deviation of nave mice (1.31%).

[0161] FIGS. 12a-12b depict how E7-specific T helper type 1 cells are induced following vaccination with the E7.sup.43-77 35-mer. Sets of 5 Mice (B6) were injected subcutaneously with E7.sup.43-77 35-mer admixed with IFA (A) or CpG (B). Spleens were harvested after 10-days and spleen cells cultures were stimulated with D1 cells pulsed with the E7.sup.43-77 35-mer. After 1 week of in vitro stimulation the specificity of the CD4+ fraction of the cultures was tested by measuring the IFN- production of individual T cells. White columns illustrate background IFN- production by CD4+ T-helper cells stimulated with non-pulsed D1 cells, whereas black columns represent IFN- production by CD4+ T-helper cells when stimulated with E7.sup.43-77 35-mer pulsed D1 cells. Each set of two columns represents an individual mouse.

[0162] FIGS. 13a-13f depict a single vaccination of the E7.sup.43-77 35-mer combined with DC-activating adjuvantia results in high CTL responses. Mice (B6) were only primed and not boosted with the E7.sup.49-57 peptide (depicted on the left) or the 35-mer (depicted on the right). Anti CD40 Ab (FIG. 13a), GM-CSF (FIG. 13b), GM-CSF plus IFA (FIG. 13c), MPL (FIG. 13d) and ODN-CpG (FIG. 13e) were used as adjuvants. Similarly, MHC class II.sup./ mice were only primed and not boosted with the E7.sup.43-77 35-mer and ODN-CpG (FIG. 13f). Spleens were harvested after 10-days and cultures were in vitro stimulated with the E7.sup.49-57-expressing tumor cell line 13.2 for 7 days. Subsequently, the percentage of E7 .sup.49-57-tetramer-positive CD8+ cells was determined by FACS-analysis (y-axis). Each column on the x-axis represents an individual mouse. The horizontal line indicates background responses plus standard deviation of naive mice (1,31%).

[0163] FIGS. 14a-14c depict the outgrowth of HPV16 E7 positive tumors in either TC-1 tumor challenged mice that were vaccinated with either the minimal CTL epitope E.sup.7.sub.49-57 mixed with a dendritic cell activating agent (CpG) (FIG. 14b; n=9 mice) or vaccinated with HPV16 E7.sup.43-77 mixed with a dendritic cell activating adjuvant (CpG) (FIG. 14c; n=10 mice) or not vaccinated (FIG. 14a; n=10 mice) at the day that all mice had small palpable tumors (day 10). Mice were boosted 14 days later and tumor outgrowth was followed for 65 days after the first immunization. Note that tumor volumes started to decrease 7-10 days after immunization and they had reached volumes of 200-500 mm3. Furthermore, non-immunized mice died 2-3 days after such a tumor volume was reached. 6/9 mice vaccinated with the minimal epitope died of their tumor, whereas 8/10 mice vaccinated with the long peptide completely eradicated their tumor.

[0164] FIGS. 15a-15c. depict the proliferation of human CD4+ T-helper clones stimulated with peptide E2.sub.46-75 that recognizes naturally processed Ag. PBMC from a healthy HLA DR4 positive blood donor were stimulated four times with peptides E2.sub.46-75. FIGS. 15a and 15b are entitled E2 51-70 specific clone 47 peptide and protein recognition, and HLA-DR restriction. Specific proliferation of the T-helper cell clone 47 against peptide E2.sub.46-75 and the N-terminal E2 protein but not the C-terminal half of the E2 protein (left, 15a) and the restriction via HLA DR4 (right, 15b) is shown. FIG. 15c is entitled E2 61-75 specific clone 36 peptide recognition. The peptide-specificity of T-helper clone 36 that recognizes a different, yet overlapping, peptide E2.sub.61-75 is shown at the bottom (FIG. 15c). (See, also, FIGS. 1a-1d and associated descriptions).

[0165] FIGS. 16a-16d depict a peptide E6.sub.127-158 induced T-cell response that recognizes naturally processed Ag. PBMC from a healthy HLA-DR1 positive blood donor were stimulated four times with peptide E6.sub.127-158. FIGS. 16a and 16b are entitled E6.sub.127-158 stimulated HLA-DR1+ PBMC. Proliferation of the bulk T-cell culture (top, left, 16a) and IFN production (top, right, 16b) is depicted. FIGS. 16c and 16d are entitled E6.sub.127-158 stimulated PBMC derived clone 9 HLA-DR restriction in proliferation and IFN production. The specific proliferation (bottom, left, 16c) and IFN production (bottom, right, 16d) of the T-helper clone, derived from the bulk T-cell culture, and HLA-restriction when stimulated with E6.sub.127-158, or E6protein is depicted. (See, also, FIGS. 1a-1d and associated descriptions).

REFERENCES

[0166] Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D. J., Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res, 25,3389-402 (1997). [0167] BARRASSO, R., DE BRUX, J., CROISSANT, O. AND ORTH, G., High prevalence of papillomavirus-associated penile intraepithelial neoplasia in sexual partners of women with cervical intraepithelial neoplasia. N. Engl. J. Med., 317,916-23 (1987). [0168] BAUR, M. P., NEUGEBAUER, M. AND DEPPE, H., Population analysis on the basis of deduced haplotypes from random families. In : E. D. Albert, M. P. Baur and W. R. Mayr (eds.), Histocompatibility Testing, pp. 333-341, Springer-Verlag, Berlin (1984). [0169] Bermas, B. L. and Hill, J. A., Proliferative responses to recall antigens are associated with pregnancy outcome in woman with a history of recurrent spontaneous abortion. J Clin Invest, 100,1330-4. (1997). [0170] Borysiewicz, L. K., Fiander, A., Nimako, M., Man, S., Wilkinson, G. W. G., Westmoreland, D., Evans, A. S., Adams, M., Stacey, S. N., Boursnell, M. E. G., Rutherford, E., Hickling, E. and Inglis, S. C., A recombinant vaccina virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet, 347,1523 1527 (1996). [0171] BOSCH, F. X., MANOS, M. M., MUNOZ, N., SHERMAN, M., JANSEN, A. M., PETO, J., SCHIFFMAN, M. H., MORENO, V., KURMAN, R. AND SHAH, K. V., Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst, 87,796-802 (1995). [0172] BRISTOL, J. A., C. ORSINI, P. LINDINGER, J. THALHAMER, AND S. 1. ABRAMS. 2000. Identification of a ras oncogene peptide that contains both CD4 (+) and CD8 (+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization. Cell Immunol 205:73. [0173] CLAAS, E. C., MELCHERS, W. J., VAN DER LINDEN, H. C., LINDEMAN, J. AND QUINT, W. G., Human papillomavirus detection in paraffin-embedded cervical carcinomas and metastases of the carcinomas by the polymerase chain reaction. Am J Pathol, 135,703-9 (1989). [0174] Clerici, M., Merola, M., Ferrario, E., Trabattoni, D., Villa, M. L., Stefanon, B., Venzon, D. J., Shearer, G. M., De Palo, G. and Clerici, E., Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J. Natl. Cancer Inst., 89,245-250 (1997). [0175] Coleman, N., Birley, H. D., Renton, A. M., Hanna, N. F., Ryait, B. K., Byrne, M., Taylor Robinson, D. and Stanley, M. A., Immunological events in regressing genital warts. Am. J. Clin. Pathol., 102,768-74 (1994). [0176] DAS, S. N., KHANNA, N. N. AND KHANNA, S., A multiparametric observation of immune competence in breast cancer and its correlation with tumour load and prognosis. Ann Acad Med Singapore, 14,374-81 (1985). [0177] DE BRUIJN, M. L., SCHUURHUIS, D. H., VIERBOOM, M. P., VERMEULEN, H., DE COCK, K. A., ODMS, M. E., RESSING, M. E., TOEBES, M., FRANKEN, K. L., DRIJFHOUT, J. W., OTTENHOFF, T. H., OFFRINGA, R. AND MELIEF, C. J., Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res., 58, 724-731 (1998). [0178] DE GRUIJL, T., BONTKES, H. J., WALBOOMERS, J. M. M., STUKART, M. J., DOEKHIE, F. S., REMMINK, A. J., HELMERHORST, T. J. M., VERHEIJEN, R. H. M., DUGGAN-KEEN, M. F., STERN, P. L., MEIJER, C. J. L. M. AND SCHEPER, R. J., Differential T-helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: A longitudinal study. Cancer Res., 58, 1700-1706 (1998). [0179] DYSON N, HOWLEY P M, MUNGER K, HARLOW E: The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243 (4893): 934, 1989. [0180] Ho G Y, BURK R D, FLEMING I, KLEIN R S: Risk of genital human papillomavirus infection in women with human immunodeficiency virus-induced immunosuppression. Int J Cancer 56 (6): 788, 1994 [0181] EARLY, E. AND REEN, D. J., Rapid conversion of naive to effector T cell function counteracts diminished primary human newborn T cell responses. Clin. Exp. Immunol., 116,527-33 (1999). [0182] EVANS, E. M., MAN, S., EVANS, A. S. AND BORYSIEWICZ, L. K., Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res., 57,2943-2950 (1997). [0183] FELTKAMP M C, SMITS H L, VIERBOOM M P, MINNAAR R P, DE JONGH B M, DRIJFHOUT J W, TER SCHEGGET J, MELIEF C J, KAST W M: Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23 (9): 2242,1993 [0184] Franken, K. L., Hiemstra, H. S., van Meijgaarden, K. E., Subronto, Y., den Hartigh, J., Ottenhoff, T. H. and Drijfhout, J. W., Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent. Protein Expr Purif, 18,95-9 (2000). [0185] Fu T M, Guan L, Friedman A, Schofield T L, Ulmer J B, Liu M A, et al., Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. J Immunol 1999; 162 (7): 4163-4170. [0186] Geluk, A., Taneja, V., Van Meijgaarden, K. E., Zanelli, E., Abou-Zeid, C., Thole, J. E., de Vries, R. R., David, C. S. and Ottenhoff, T. H., Identification of HLA class 11-restricted determinants of Mycobacterium tuberculosis-derived proteins by using HLA-transgenic, class II-deficient mice. Proc. Natl. Acad. Sci. U.S.A., 95,10797-10802 (1998). [0187] GELUK, A., VAN MEIJGAARDEN, K. E., DRIJFHOUT, J. W. AND OTTENHOFF, T. H., Clip binds to HLA class II using methionine-based, allele-dependent motifs as well as alleleindependent supermotifs. Mol. Immunol., 32, 975 981 (1995). [0188] GHOSH, P., KOMSCHLIES, K. L., CIPPITELLI, M., LONGO, D. L., SUBLESKI, J., YE, J., SICA, A., YOUNG, H. A., WILTROUT, R. H. AND OCHOA, A. C., Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst, 87, 1478-83 (1995). [0189] HALPERT R, FRUCHTER R G, SEDLIS A, BUTT K, BOYCE J G, SILLMAN F H : Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet Gynecol 68 (2): 251,1986 [0190] HAN R, CLADEL N M, REED C A, PENG X, CHRISTENSEN N D : Protection of rabbits from viral challenge by gene gun-based intracutaneous vaccination with a combination of cottontail rabbit papillomavirus E1, E2, E6, and E7 genes. J Virol 73 (8): 7039,1999. [0191] HIRANUMA, K., S. TAMAKI, Y. NISHIMURA, S. KUSUKI, M. ISOGAWA, G. Mm, M. KAITO, K. KURIBAYASHI, Y. ADACHI, AND Y. YASUTOMI. 1999. Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus. J Gen Virol 80:187. [0192] Ho GY, Bierman R, BEARDSLEY L, CHANG C J, BURK RD : Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338 (7): 423, 1998. [0193] HOHN, H., PILCH, H., GUNZEL, S., NEUKIRCH, C., HILMES, C., KAUFMANN, A., SELIGER, B. AND MAURER, M. J., CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7. J Immunol., 163,5715-22 (1999). [0194] HOPFL, R., WIDSCHWENDTER, A., CHRISTENSEN, N. D., WIELAND, U., ZUMBACH, K., SANDRA, H., PFISTER, H. J., PAWLITA, M. AND HEIM, K., Delayed-type hypersenstivity to HPV16 E7 and humoral immunity to HPV16/18 E6, E7 and HPV 6/11/16/18/31 LI-virus like particles in women with cervical neoplasia. In : X. Castellsague, F. X. Bosch, S. de Sanjose, V. Moreno and J. Ribes (eds.), 18th international papillomavirus conference, pp.299, Institut Catale d'Oncologia, Barcelona, Spain (2000). [0195] JONDAL M, SCHIRMBECK R, REIMANN J : MHC class I-restricted CTL responses to exogenous antigens. Immunity 5 (4): 295,1996 [0196] Karlsson, R., Jonsson, M., Edlund, K., Evander, M., Gustaysson, A., Boden, E., Rylander, E. and Wadell, G., Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population-based study. Sex Transm Dis, 22,119-27 (1995). [0197] KAST W M, ROUXL, CURRENJ, BLOMHJ, VOORDOUWAC, MELOENRH, KOLAEOFSKYD, MELIEF C J: Protection against lethal Sendai virus infection by in vivo priming of virusspecific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl. Acad. Sci. U.S.A.88 (6): 2283,1991 [0198] KOUTSKY L: Epidemiology of genital human papillomavirus infection. Am J Med 102 (5A): 3,1997. [0199] KURTS C, CARBONE F R, BARNDENM, BLANAS E, ALLISON J, HEATH W R, MILLER J F: CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self antigens and favors autoimmunity. J Exp Med 186 (12): 2057,1997 [0200] Manca, F., Li Pira, G., Fenoglio, D., Fang, S. P., Habeshaw, A., Knight, S. C. and Dalgleish, A. G., Dendritic cells are potent antigen-presenting cells for in vitro induction of primary human CD4+ T-cell lines specific for HIV gp 120. J Acquir Immune Defic Syndr, 7,15-23 (1994). [0201] MARRAZZO J M, STINE K, KOUTSKY L A : Genital human papillomavirus infection in women who have sex with women: a review. Am J Obstet Gynecol 183 (3): 770,2000 [0202] MATORRAS R, ARICETA J M, REMENTERIA A, CORRAL J, GUTIERREZ DE TERAN G, DIEZ J, MONTOYA F, RODRIGUEZ-ESCUDERO F J: Human immunodeficiency virus-induced immunosuppression: a risk factor for human papillomavirus infection. Am J Obstet Gynecol 164 (1 Pt 1): 42,1991 [0203] McCutcheon, M., Wehner, N., Wensky, A., Kushner, M, Doan, S., Hisao, L., Calabresi, P., Ha, T., Tran, T. V., Tate, K. M., Winkelhake, J. and Spack, E. G., A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Methods, 210,149-66 (1997). [0204] MELIEF, C. J. M., TOES, R. E. M., MEDEMA, J. P., VAN DER BURG, S. H., OSSENDORP, F. AND OFFRINGA, R., Strategies for Immunotherapy of Cancer. Adv. Immunol., 75,235-281 (2000). [0205] Mellman, I., Turley, S. J. and Steinman, R. M., Antigen processing for amateurs and professionals. Trends Cell Biol, 8, 231-7 (1998). [0206] NAIPAL, A. M., D'AMARO, J., RUNING, J. W., VANLEEUWEN, A. AND VAN ROOD, J. J., Automated reading of Propidium Iodide lymphocytotoxicity tests for HLA-DR, MB, MT typing. Tissue Antigens, 24,302-6 (1984). [0207] NIMAKO, M., FINDER, A., WILKINSON, G. W. G., BORYSIEWICZ, L. K. AND MAN, S., Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Res., 57,4855-4861 (1997). [0208] OSSENDORP F, MENGEDE E, CAMPS M, FILIUS R, MELIEF C J M: Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class Il negative tumors. J. Exp. Med. 187 (5): 1, 1998. [0209] PARDOLL, D. M. AND TOPALIAN, S. L., The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol., 10,588-94 (1998). [0210] Pittet, M. J., Valmori, D., Dunbar, P. R., Speiser, D. E., Lienard, D., Lejeune, F., Fleischhauer, K., Cerundolo, V., Cerottini, J. C. and Romero, P., High frequencies of naive Melan-A/MART-1-specific CD8 (+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med., 190,705-15 (1999). [0211] RAIVIMENSEE, H. G., FRIEDE, T. AND STEVANOVIIC, S., MEW ligands and peptide motifs: first listing. Immunogenetics, 41,178-228 (1995). [0212] REIMANN J, KAUFMANN S H: Alternative antigen processing pathways in anti-infective immunity. Curr Opin Immunol 9 (4): 462,1997 [0213] RESSING, M. E., SETTE, A., BRANDT, R. M. P., RUPPERT, J., WENTWORTH, P. A., HARTMAN, M., OSEROFF, C., GREY, H. M., MELIEF, C. J. M. AND KAST, W. M., Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201 binding peptides. J. Immunol., 154,59345943 (1995). [0214] RESSING, M. E., VAN DRIEL, W. J., BRANDT, R. M., KENTER, G. G., DE JONG, J. H., BAUKNECHT, T., FLEUREN, G. J., HOOGERHOUT, P., OFFRINGA, R., SETTE, A., CELIS, E., GREY, H., TRIMBOS, B. J., KAST, W. M. AND MELIEF, C. J., Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J. Immunother., 23,25566 (2000). [0215] RESSING, M. E., VANDRIEL, W. J., CELIS, E., SETTE, A., BRANDT, R. M. P., HARTMAN, M., ANHOLTS, J. D. H., SCHREUDER, G. M. T., TER HARMSEL, W. B., FLEURE, G. J., TRIMBOS, B. J., KAST, W. M. AND MELIEF, C. J. M., Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Res., 56,582-588 (1996). [0216] Rodriguez, A., Regnault, A., Kleijmeer, M., Ricciardi-Castagnoli, P. and Amigorena, S., Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol, 1, 362-8 (1999). [0217] SCHEFFNER M, WERNESS B A, HUIBREGTSE J M, LEVINE A J, HOWLEY P M: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 (6): 1129,1990. [0218] SCHOENBERGER S P, TOES R E, VAN DER VOORT E I, OFFRINGA R, MELIEF C J: T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393 (6684): 480,1998. [0219] Sedlik C, Dadaglio G, Saron M F, Deriaud E, Rojas M, Casal SI, et al., In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity. J Virol 2000; 74 (13) : 5769-5775. [0220] SELVAKUMAR R, BORENSTEIN L A, LIN Y L, AHMED R, WETTSTEIN F O: Immunization with non-structural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J Virol 69 (1) : 602,1995. [0221] SHIRAI, M., C. D. PENDLETON, J. AHLERS, T. TAKESHITA, M. NEWMAN, AND J. A. BERZOF SKY. 1994. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J Immunol 152:549. [0222] Thomas, K. K., Hughes, J. P., Kuypers, J. M., Kiviat, N. B., Lee, S. K., Adam, D. E. and Koutsky, L. A., Concurrent and sequential acquisition of different genital human papillomavirus types [In Process Citation]. J Infect Dis, 182,1097-102 (2000). [0223] TOES R E, OFFRINGA R, BLOM R J, MELIEF C J, KAST W M: Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 93 (15): 7855, 1996a. [0224] TOES R E, BLOM R J, OFFRINGA R, KAST W M, MELIEF C J: Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol 156 (10): 3911,1996b [0225] TOES, R. E. M., OSSENDORP, F., OFFRINGA, R. AND MELIEF, C. J. M., CD4 T cells and their role in antitumor immune responses. J. Exp. Med., 189,753-756 (1999). [0226] VAN DER BURG, S. H., KWAPPENBERG, K. M., GELUK, A., VANDER KRUK, M., PONTESILLI, O., HOVENKAMP, E., FRANKEN, K. L., VANMEIJGAARDEN, K. E., DRIJFHOUT, J. W., OTTENHOFF, T. H., MELIEF, C. J. AND OFFRINGA, R., Identification of a conserved universal Th epitope in HIV-1 reverse transcriptase that is processed and presented to HIV-specific CD4+ T cells by at least four unrelated HLA-DR molecules. J. Immunol., 162,152-60 (1999). [0227] VAN DER BURG, S. H., K. M. C. KWAPPENBERG, T. ONEILL, R. M. P. BRANDT, C. J. M. MELIEF, J. K. HICKLING, R. OFFRINGA (2001): Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine, 19: 3652-3660 [0228] WANEBO, H. J., JUN, M. Y., STRONG, E. W. AND OETTGEN, H., T-cell deficiency in patients with squamous cell cancer of the head and neck. Am J Surg, 130,445-51 (1975). [0229] ZUR HAUSEN H: Papillomavirus infections-a major cause of human cancers. Biochimica et Biophysica Acta 1288: F55,1996.